Press releases
2023
26 April, 2023
Interim report January-March 2023
30 March, 2023
Egetis comments on market rumors
28 March, 2023
Egetis Therapeutics’ 2022 annual report published
22 February, 2023
Year-end Report Q4 2022
31 January, 2023
Change in the number of shares and votes in Egetis Therapeutics
25 January, 2023
Egetis Therapeutics has successfully carried out a directed share issue amounting to SEK 210 million
24 January, 2023
Egetis Therapeutics announces the intention to carry out a directed share issue of approximately SEK 200 million
2022
8 November, 2022
Interim report January-September 2022
19 August, 2022
Interim report Q2 2022
19 May, 2022
Egetis Therapeutics raises approximately SEK 180 million through an oversubscribed rights issue
26 April, 2022
Interim report January-March 2022
20 April, 2022
Egetis Therapeutics’ 2021 annual report published
13 April, 2022
Bulletin from extraordinary shareholders’ meeting in Egetis Therapeutics AB and publication of timetable relating to the rights issue
21 March, 2022
Egetis Therapeutics resolves on a fully guaranteed preferential rights issue of approximately SEK 180 million